Yes Stay, has been a strong performer. Thanks for sharing that.
Better news is it is going to be very busy year on the trial front, going to find out a lot about Idronoxil-C's potential in various trial settings.
Great stock to be involved in and buyers chipping away at it this week. Potential is huge.
Add to My Watchlist
What is My Watchlist?
